shorts throwing new/good money after bad/losses. This could get ugly for them soon. Better send some more money to AF and friends, maybe you'll get into the Friday mail bag.
I was half a day, or a day early on the swap, but I think EXAS has bottomed and is about to go much higher. IMO, not advice. I still have plenty of IMGN. It's very difficult to predict the timing due to news and shorting. They took my 5K sale and other sales with a fairly strong bid, so I thought the price might be firm here. IMO, not advice.
Looks like a technical test is coming soon. Nice move so far, let's see if it can hold up, or push through.
Anyone here own EXAS? Might want to take a look ASAP.
I am going to print the PDF doc and bring it to my Doc soon. He gave me the FIT test last year and I never did it. Sounded too messy and I knew Colo would be approved soon.
MNKD is a loser, EXAS will be a large LT winner, maybe just not today. Company needs to get busy spreading the word and creating demand for their product AND their stock to drive away the criminal bio-shorts (I really despise them). Checking some of the employees listed on Linked-in I see a lot of former GE people now employed at EXAS.
yep, heavily shorted stocks, that start the day up big, are always shorted and beaten down. I think the future is bright for this company, demand will be high. I am of the age and have put off the colonoscopy waiting for this product to be approved. I will be calling my insurance company, then my MD to get the test soon.
I fired him today, sold 2/3 of my position and bought another stock. Tire of losing $, took the tax loss, moving on for now, may be back later. Still have some shares, but not a large position.
sold 1/3 of my IMGN and 2/3 of my ARNA position to buy EXAS. I still own plenty/too much IMGN considering its terrible performance. ARNA is just getting killed by the shorts and weak leadership is also not helping them. I think the EXAS product will be a big seller and the company price could easily double again (or more) in the next 12-24 months. IMO, not advice.
Agreed, I don't get the market cap. I guess the product is not sexy enough. Maybe shorts are hoping for another offering. I bought some stock today, will buy some more if it goes lower. I have other stocks that are higher risk with similar growth potential, seems like a no-brainer.
Thanks, have you seen any rev projections based on just colon? Based on the interview this morning, I was thinking $4BB peak sales in the US and another $4BB outside the US was possible. How quickly can they ramp this up? Do they need more cash?
Anyone know what they have in the pipeline checked the web sire, but was not able to find anything about a pipeline. Sounds like Colo can generate $4BB in revs in the US alone. I's surprised some has not already acquired EXAS, but at this low price, I doubt they are open to selling. Do they have a distribution partner, or is this product still wholly-owned? I probably should have know the answer to this before investing.
Tired of fighting these morons, sold a small portion of my position to buy some EXAS. Probably selling low and buying high. Hard to believe EXAS has 25MM shares short.
I doubt they are working to hard on acquisitions at this point, their full 100% attention needs to be on filing and launch. If they get the filing and launch right, they can either sell the company, or expand through acquisition if they find something suitable to acquire (ARNA). I don't see this happening anytime soon.
Is this for the current form of Bel, or something new?
I think this has been enrolling slowly due to high tox issues with the early, over-weight patients. Maybe now that they figured out the ideal body weight issue/solution, enrollment will speed up.
40MM range, seems strange and I wonder if there are naked shorts that are not being reported. I have a difficult time believing shorts were net buyers.
Scary because shorts tend to be smart and well informed, exciting because those shares need to be covered eventually. Net result is higher volatility should be expected.
From the FDA web site. Really, 4 years for a phase I study?
Estimated Enrollment: 46
Study Start Date: January 2012
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure